AU6677000A - Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen - Google Patents

Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen

Info

Publication number
AU6677000A
AU6677000A AU66770/00A AU6677000A AU6677000A AU 6677000 A AU6677000 A AU 6677000A AU 66770/00 A AU66770/00 A AU 66770/00A AU 6677000 A AU6677000 A AU 6677000A AU 6677000 A AU6677000 A AU 6677000A
Authority
AU
Australia
Prior art keywords
ctls
cd40l
lymphocytes
antigen
vivo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU66770/00A
Inventor
Pamela S. Ohashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Original Assignee
University Health Network
University of Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network, University of Health Network filed Critical University Health Network
Publication of AU6677000A publication Critical patent/AU6677000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU66770/00A 1999-08-27 2000-08-23 Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen Abandoned AU6677000A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38486299A 1999-08-27 1999-08-27
US09/384862 1999-08-27
PCT/CA2000/000960 WO2001015728A1 (en) 1999-08-27 2000-08-23 Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen

Publications (1)

Publication Number Publication Date
AU6677000A true AU6677000A (en) 2001-03-26

Family

ID=23519063

Family Applications (1)

Application Number Title Priority Date Filing Date
AU66770/00A Abandoned AU6677000A (en) 1999-08-27 2000-08-23 Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen

Country Status (2)

Country Link
AU (1) AU6677000A (en)
WO (1) WO2001015728A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ755300A0 (en) 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
US20040247563A1 (en) * 2000-11-02 2004-12-09 Lynch David H. Method of enhancing lymphocyte-mediated immune responses
GB0225736D0 (en) * 2002-11-05 2002-12-11 Adjuvantix Ltd T-Cell Independent Vaccine
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0703976D0 (en) * 2007-03-02 2007-04-11 Adjuvantix Ltd Liposome preparation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874085A (en) * 1993-11-10 1999-02-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Vaccine for enhanced production of IgA antibodies
CA2207246A1 (en) * 1997-06-06 1998-12-06 The University Of Sheffield Vaccine development
AU765822B2 (en) * 1998-05-23 2003-10-02 Leiden University Medical Center CD40 binding molecules and CTL peptides for treating tumors

Also Published As

Publication number Publication date
WO2001015728A1 (en) 2001-03-08

Similar Documents

Publication Publication Date Title
AU2707100A (en) System and sequential culture media for in vitro fertilization
AU7580600A (en) System and method for programmably dispensing material
AU6929100A (en) Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
AU2002322211A1 (en) Methods and compisitions for activation human t cells in vitro
AU6894700A (en) Therapeutic polypeptides and methods for using same
AU2001276831A1 (en) Delivery vehicle composition and methods for delivering antigens and other drugs
AU7847400A (en) Method for determining and modifying protein/peptide solubility
AU1329799A (en) Use of a soluble recombinant human cd40l protein for inhibiting (in vivo) immuneresponse
AU6677000A (en) Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen
AU1954301A (en) Method and device for surgical bone grinding
AU2002219993A1 (en) Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
AU5778400A (en) Prion protein binding proteins and uses thereof
AU7308200A (en) Novel hev antigenic peptide and methods
AU2242897A (en) Protein occlusion for delivery of small molecules
AU2001293124A1 (en) System and method for per use no-answer message delivery
AU2753600A (en) A method for targeted degradation of intracellular proteins (in vivo) or (ex vivo)
AU2001281002A1 (en) Motor proteins and methods for their use
AU2002245979A1 (en) Process for making protein delivery matrix and uses thereof
AU3152797A (en) Methods for (in vitro) protein synthesis
AU2002226980A1 (en) Sampling and storage system for genetic material from tissue
AU3926000A (en) Methods and compositions for drug delivery
AU2001266961A1 (en) Novel motor proteins and methods for their use
AU1224601A (en) In vitro embryo culture device and methods
AU4866201A (en) Compositions and methods for use in modulating immune system function
AU2001289603A1 (en) Methods and means for the complementation of viral protein expression in stable cell lines

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase